BR112021021176A2 - Proteína de fusão, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema de complemento de um indivíduo, célula, e, animal não humano geneticamente modificado - Google Patents
Proteína de fusão, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema de complemento de um indivíduo, célula, e, animal não humano geneticamente modificadoInfo
- Publication number
- BR112021021176A2 BR112021021176A2 BR112021021176A BR112021021176A BR112021021176A2 BR 112021021176 A2 BR112021021176 A2 BR 112021021176A2 BR 112021021176 A BR112021021176 A BR 112021021176A BR 112021021176 A BR112021021176 A BR 112021021176A BR 112021021176 A2 BR112021021176 A2 BR 112021021176A2
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- complement
- fusion protein
- treating
- disease
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 6
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 230000001404 mediated effect Effects 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 230000024203 complement activation Effects 0.000 title abstract 2
- 230000004154 complement system Effects 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 230000000295 complement effect Effects 0.000 abstract 3
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0387—Animal model for diseases of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
proteína de fusão, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema de complemento de um indivíduo, célula, e, animal não humano geneticamente modificado. esta invenção se refere à inibição da sinalização do complemento usando um anticorpo anti-c5 ou proteína de fusão do mesmo. especificamente, a invenção se refere a métodos para tratar uma doença mediada por complemento ou distúrbio mediado por complemento em um indivíduo pelo contato do indivíduo com uma proteína de fusão de anticorpo anti-c5 do mesmo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962837833P | 2019-04-24 | 2019-04-24 | |
US201962837853P | 2019-04-24 | 2019-04-24 | |
PCT/US2020/029876 WO2020219922A1 (en) | 2019-04-24 | 2020-04-24 | Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021021176A2 true BR112021021176A2 (pt) | 2021-12-28 |
Family
ID=72941382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021021176A BR112021021176A2 (pt) | 2019-04-24 | 2020-04-24 | Proteína de fusão, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema de complemento de um indivíduo, célula, e, animal não humano geneticamente modificado |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220204602A1 (pt) |
EP (1) | EP3958901A4 (pt) |
JP (1) | JP2022529527A (pt) |
KR (1) | KR20220003001A (pt) |
CN (1) | CN114072174A (pt) |
AU (1) | AU2020261073A1 (pt) |
BR (1) | BR112021021176A2 (pt) |
CA (1) | CA3137907A1 (pt) |
IL (1) | IL287232A (pt) |
MX (1) | MX2021012997A (pt) |
SG (1) | SG11202111419QA (pt) |
WO (1) | WO2020219922A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220177556A1 (en) * | 2018-09-06 | 2022-06-09 | The Trustees Of The University Of Pennsylvania | Humanized anti-c5 antibodies and uses thereof |
WO2023197930A1 (zh) * | 2022-04-11 | 2023-10-19 | 天辰生物医药(苏州)有限公司 | 补体抑制杂合蛋白 |
CN117624347A (zh) * | 2022-08-30 | 2024-03-01 | 天辰生物医药(苏州)有限公司 | 抗人补体c5抗体以及其融合蛋白 |
WO2024097796A1 (en) | 2022-11-02 | 2024-05-10 | Kira Pharmaceuticals (Us) Llc | Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases |
WO2024097441A1 (en) | 2022-11-02 | 2024-05-10 | Kira Pharmaceuticals (Us) Llc | Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2717912T3 (es) * | 2010-05-14 | 2019-06-26 | Univ Colorado Regents | Grupos dirigidos al receptor del complemento 2 (cr2) mejorados |
EP3473272A1 (en) * | 2013-03-29 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
RU2020103811A (ru) * | 2014-05-05 | 2020-02-18 | Регенерон Фармасьютикалз, Инк. | Гуманизированные животные по с5 и с3 |
RU2742606C2 (ru) * | 2015-12-18 | 2021-02-09 | Чугаи Сейяку Кабусики Кайся | Антитела к с5 и способы их применения |
WO2017114401A1 (zh) * | 2015-12-31 | 2017-07-06 | 江苏匡亚生物医药科技有限公司 | 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用 |
SG10201800265UA (en) * | 2016-06-17 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
WO2018024162A1 (en) * | 2016-08-03 | 2018-02-08 | Sunshine Lake Pharma Co., Ltd. | Glp-1 fusion protein comprising mutated immunoglobulin fc portion |
CA3055541A1 (en) * | 2017-03-06 | 2018-09-13 | The Trustees Of The University Of Pennsylvania | Anti-c5 antibodies and uses thereof |
US20220177556A1 (en) * | 2018-09-06 | 2022-06-09 | The Trustees Of The University Of Pennsylvania | Humanized anti-c5 antibodies and uses thereof |
-
2020
- 2020-04-24 MX MX2021012997A patent/MX2021012997A/es unknown
- 2020-04-24 SG SG11202111419QA patent/SG11202111419QA/en unknown
- 2020-04-24 JP JP2021563186A patent/JP2022529527A/ja active Pending
- 2020-04-24 WO PCT/US2020/029876 patent/WO2020219922A1/en unknown
- 2020-04-24 US US17/605,695 patent/US20220204602A1/en active Pending
- 2020-04-24 BR BR112021021176A patent/BR112021021176A2/pt unknown
- 2020-04-24 KR KR1020217038290A patent/KR20220003001A/ko unknown
- 2020-04-24 CN CN202080046514.4A patent/CN114072174A/zh active Pending
- 2020-04-24 AU AU2020261073A patent/AU2020261073A1/en active Pending
- 2020-04-24 EP EP20795853.9A patent/EP3958901A4/en active Pending
- 2020-04-24 CA CA3137907A patent/CA3137907A1/en active Pending
-
2021
- 2021-10-13 IL IL287232A patent/IL287232A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220003001A (ko) | 2022-01-07 |
CN114072174A (zh) | 2022-02-18 |
WO2020219922A1 (en) | 2020-10-29 |
CA3137907A1 (en) | 2020-10-29 |
JP2022529527A (ja) | 2022-06-22 |
SG11202111419QA (en) | 2021-11-29 |
IL287232A (en) | 2021-12-01 |
EP3958901A4 (en) | 2023-07-19 |
AU2020261073A1 (en) | 2021-12-16 |
US20220204602A1 (en) | 2022-06-30 |
EP3958901A1 (en) | 2022-03-02 |
MX2021012997A (es) | 2022-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021021176A2 (pt) | Proteína de fusão, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema de complemento de um indivíduo, célula, e, animal não humano geneticamente modificado | |
BR112019009316A2 (pt) | anticorpo antirreceptor de transferrina humana, proteína de fusão, fragmento de dna, vetor de expressão, célula de mamífero, complexo de composto farmacologicamente ativo e de anticorpo antirreceptor de transferrina humana, usos do anticorpo antirreceptor de transferrina humana e da proteína de fusão, e, métodos para tratamento de um distúrbio do sistema nervoso central e de uma doença do sistema nervoso central que acompanha a doença de pompe, a síndrome de hurler ou a síndrome de hurler-scheie. | |
BR112016017248A8 (pt) | anticorpo ou fragmento seu, agente de ligação, animal transgênico, hibridoma, vetor, composição farmacêutica, método de indução de sinalização de semelhantes a fgf19 e/ou fgf21, método para ativar um complexo klotho beta/receptor de fgf, método para melhorar o metabolismo da glicose em um indivíduo, método de detecção da presença de klotho beta, uso do anticorpo ou fragmento seu, uso da composição farmacêutica, método de tratamento e método para melhorar parâmetros metabólicos | |
EA201992091A1 (ru) | Анти-c5 антитела и их применение | |
BR112017028353A2 (pt) | anticorpos para cd40 com atividade agonista melhorada | |
BR112018069297A2 (pt) | composição, e, métodos para induzir uma resposta imune e para tratar um indivíduo que foi diagnosticado com uma doença ou distúrbio | |
BR112019022538A8 (pt) | Técnicas para pareamento comportamental em um sistema de centro de contato | |
CO2017009061A2 (es) | Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenes | |
BR112016024515A2 (pt) | proteínas do agonista do receptor trail de cadeia única | |
BR112017019978A2 (pt) | anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo | |
BR112019004733A2 (pt) | métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1 | |
AR105767A1 (es) | Proteínas de fusión de unión a gitr multivalentes y multiespecíficas | |
MX2023000738A (es) | Proteinas de union a antigeno que activan el receptor de leptina. | |
BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
BR112018003535A2 (pt) | receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, e, uso de um vetor de expressão | |
BR112017018770A2 (pt) | redução da tolerância imunológica induzida por pd-l1 | |
AR084373A1 (es) | Composiciones y metodos para la eliminacion de biopeliculas | |
MX2021002710A (es) | Anticuerpos anti-c5 humanizados y usos de los mismos. | |
BRPI0906550B8 (pt) | Anticorpo anti-tigit, usos de um anticorpo anti-tigit e métodos in vitro para estimular a interação de cd226-pvr e/ou a interação de cd96-pvr, para aumentar ou estimular a proliferação de uma célula t ou a liberação de citocinas proinflamatórias por uma célula dendrítica, para aumentar ou estimular a resposta imune de célula t e para aumentar ou estimular a produção de citocinas proinflamatórias por uma célula dendrítica | |
BRPI0907735A2 (pt) | anticorpo, ácido nucleico isolado, célula hospedeira, camundongo transgênico, hibridoma, composição farmacêutica, método para tratar uma condição ou uma doença associada a um distúrbio imune, cristal, proteína de fusão, e, método para preparar o anticorpo | |
CL2018000750A1 (es) | Método de redireccionamiento de linfocitos t para el tratamiento de la infección por vih | |
MX2019009546A (es) | Anticuerpos anti-factor d y uso de los mismos. | |
BR112016019057A2 (pt) | método de induzir uma resposta imune contra uma doença em um indivíduo | |
BR112019011860A2 (pt) | proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune | |
BR112017003620A2 (pt) | métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos |